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INTRODUCTION
Colin: This year marks the 19th volume of Jefferson’s
annual publication spearheaded by Internal Medicine
residents and supported by its fellows. Our Editorial Board
includes Neha, Debbie, Anita, Brianna, and myself. Our
mission is to further medical knowledge by sharing each
other’s observations and studies both through our
publication, which you can find online, as well as through
annual discussion at Grand Rounds.
This year, we’ve chosen to focus on our roles as providers
in the midst of the National Opioid Epidemic. The
National Institute on Drug Abuse has reported that the
number of opioid-related overdose deaths from both
illegal and prescription opioids has risen in our state over
the last 15 years. This information is available for each
state online. While addiction has been a nationwide
issue for centuries, provider practices and societal
attitudes in relation to opioids has greatly varied. We’ll
introduce you to our panelists, giving a very brief
overview of the history of opioid use in our country, then
turning the discussion over to them.

Today, we have Dr. Abigail Kay, Assistant Dean of Academic
Affairs and Undergraduate Medical Education and
Assistant Professor in the Department of Psychiatry and
Human Behavior. Ms. Meghan Morley is the Lead Patient
Navigator at the Center of Excellence at the Narcotic
Addiction Rehabilitation Program (NARP) in the Division of
Substance Abuse. Dr. Rachel Nash is a current Chief
Resident in the Department of Internal Medicine. Ms. Kate
Siddiqi is a social worker at Jefferson. Dr. Brooke Worster
is an Assistant Professor of Palliative Care in the
Department of Family and Community Medicine. Dr. Jill
Zavodnick is a hospitalist at Jefferson. Drs. Kay, Nash, and
Zavodnick and Ms. Morley are members of Jefferson’s
Opioid Task Force, established in the fall of 2017 to provide
structure, focus, and direction to Jefferson’s response to
the current Opioid Crisis. No one involved with these
Grand Rounds has any relevant disclosures.
Brianna: First we’re going to go over some definitions so
we can all be on the same page as we move forward in
our discussion. “Opiate” is a term used to describe any
drug derived from actual opium. “Opioid” was a term
initially used to describe synthetic or semi-synthetic
versions of opiates but has now come to encompass any
agent which binds to opioid receptors in the CNS and GI
tract, including natural, synthetic, and semi-synthetic
drugs. The body produces natural, endogenous opioids
such as endorphins which are unable to independently
cause respiratory depression or adequate pain relief in
extreme circumstances. Opium alkaloids include
morphine and codeine; semi-synthetic opioids resemble
the structure of opiates and include heroin, oxycodone,
and buprenorphine; and fully synthetic opioids which
don’t resemble the structure of opiates at all include
methadone.
Prescription and illegal opioids can lead to patterns of
tolerance, dependence, and addiction with chronic use.
We’ll go over those three terms as well. Tolerance
suggests that a person require higher and/or more
frequent doses of drug to achieve desired effects such as
pain control. Dependence implies that one’s neurons
only function normally in the presence of drug and thus
that its absence results in withdrawal symptoms. Addiction
refers to compulsive or uncontrollable drug-seeking
behavior despite harmful consequences—either at work,
in relationships, with one’s health, or with the law.
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Colin: The Smithsonian published an article just last week
called “How Advertising Shaped the First Opioid Epidemic,
and What It Can Teach Us About the Second.” It sets the
stage in the 1800s, when physicians and manufacturers
who recognized the effectiveness of morphine as a
painkiller began incorporating it into many drugs. There
was no Food and Drug Administration (FDA) to regulate
safe and standardized production yet, so medicines were
sold without a full listing of their active ingredients and
often without need for a doctor’s prescription. Cocaine
and alcohol were also common additives to popular
medications then.

and fentanyl were later released for chronic non-cancer
pain and again purported to be less addictive. Educational
programs funded by pharmaceutical companies and
supported by such institutions as the American Pain
Society (APS) designated pain as “the fifth vital sign” as
recently as the 2000s and prescription opioid use peaked
in 2010 with 82 prescriptions for every 100 persons. This
takes us to present day; with the rise of opioid-related ED
visits for nonfatal overdoses as well as actual deaths, the
pendulum has swung back in the direction of discouraging
opioid use and the establishment of the Prescription Drug
Monitoring Program (PDMP).

Morphine was heralded as a cure-all, recommended by
physicians at the time for everything from wounds
obtained by soldiers during the Civil War to the menstrual
cramps and teething pains of their wives and children.
Use of IV and oral formulations of opioids was ubiquitous
and most patients who sought prescriptions were of
respectable social backgrounds. Once doctors and
journalists began to take note of the addictive nature of
these medications, the Pure Food and Drug Act was
created in 1906 and eventually gave rise to the FDA.

TRANSCRIPT

Brianna: Now I’m going to walk us through a timeline of
opioid development, which stretches back to the 1800s
all the way to today. This timeline is interesting because it
clearly demonstrates the swinging pendulum in regards
to the support and criticism surrounding the use of
opioids. We’ll start way back in the 1800s when morphine
was first isolated from plant. Merck began marketing it in
the 1820s in a pill form. Codeine was first isolated in the
1830s and used for cough. Then the syringe was invented
in 1850s and you can see morphine really came into use
in its IV form during the Civil War in the 1860s. Then, in
the 1870s, heroin was invented and marketed as a safer
drug. You’ll see this theme as we go forward—the
realization that a certain opioid or type of opioid was
addictive, government intervention, then the production
and marketing of a “safer drug.” Next, as awareness of
opioid addiction grew in the 1900s, the act giving rise to
the FDA was established. This reduced the use of
morphine both as prescribed and over-the-counter
medications, but doctors were instead encouraged to
employ “less addictive” painkillers such as oxycodone and
methadone in subsequent years.
In the 1970s, pharmaceutical companies which had
previously limited their marketing to physicians also began
redirecting their advertising to consumers directly which
contributed to a nationwide clamor for these
semi-synthetic and thus reportedly safer agents. When
the addictive nature of these agents were subsequently
elucidated, the War on Drugs was declared and the “Just
Say No” campaign launched. Just a decade later, the
Drug Enforcement Agency was also established at this
time. Extended-release versions of morphine, oxycodone,
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Colin: In the last couple years, President Trump has
declared the Opioid Crisis a national epidemic and public
health emergency, vowing to dedicate $13 billion to new
resources for addiction treatment, physician education
on appropriate prescribing, and prosecution of drug
traffickers. Most recently, the CDC has released an annual
surveillance report of drug-related risks and outcomes for
2017, reflecting on the previous year. We’ll leave up these
statistics as we begin our conversation with our panelists,
centered on our role as providers in the midst of the
Opioid Crisis. To begin, I think it would be nice to just go
down the line and explain your role and experience taking
care of patients in the Opioid Crisis.
Dr. Kay: I’m Dr. Abby Kay and from 2005-2015, I was
the Medical Director of NARP. When I became the Dean,
I switched to being a regular, everyday doctor there and
I teach both locally and nationally about how to use
medically-assisted treatment options and how to treat
addiction in general.
Dr. Worster: Hi, I’m Dr. Brooke Worster and I live in the
palliative care world so I sort of straddle this interesting
bifurcation of opioids in that we employ them often in
end-of-life care. I also live in the world of cancer pain
management and, I’m happy to report, cancer survivorship
which entails a lot of substance abuse disorders which
are often iatrogenically created. I’m a part of the Task
Force here and deal with a lot of substance abuse
disorders, opioid abuse disorders, but have to maintain
some availability because they aren’t all bad.
Dr. Nash: I’m Rachel Nash, I live in the resident world and
am one of our current chiefs. I became interested in this
topic mainly out of frustration, being on Green medicine
and being a night Medical Admitting Resident and feeling
like I was taking care of the same patients over and over
again that struggled with opioid use disorder. As a result of
that, I did additional training in addiction medicine in Boston
and have been involved in the Task Force ever since,
focusing on resident education and increasing the use of
the PDMP and familiarity with suboxone on campus here.

Dr. Zavodnick: I’m Jill Zavodnick, I’m one of the hospitalists
here which makes me a very frequent inpatient prescriber
and occasional short-term outpatient prescriber of
opioids. I’ve seen lots of the medical complications of
addiction as well as the medical consequences of our
inability to treat pain very well, so that’s part of what got
me interested in this issue—the consequences of
hospitalized addicted patients with withdrawal symptoms
that we’re not great at managing which makes us not
great at managing their other medical problems. My goal
is to help inpatient providers figure out what to do with
people who are suffering from withdrawal when they are
in the hospital partially to facilitate their medical care and
then figure out how we can use our inpatient visits as a
way to help get people more engaged and linked into
recovery.
Ms. Morley: Hi everyone, I’m Meghan Morley, the Lead
Patient Navigator at the Center of Excellence for the
Department of Psychiatry in the Division of Substance
Abuse. I’m a professional counselor and started at NARP
as a therapist doing substance abuse counseling there
for methadone maintenance patients. The Center of
Excellence is a grant that was given to the university
from Governor Tom Wolf to help connect people with
treatment through warm handoffs, and most of my efforts
are focused at Methodist Hospital but also at Main
Campus. I also work with offices that prescribe suboxone
to help people connect with counseling services, so I’m
happy to be here today to talk about our service and how
we can provide you with support in connecting your
patients with treatment.
Ms. Siddiqi: I’m Kate Siddiqi and I’m an inpatient social
worker and have been here for 14 years as of today itself.
We have a large number of patients as you’ve all
mentioned who have cycled back through, and it’s very
frustrating but we’ve had success from Meghan and the
Center of Excellence connecting people to the outside.
There are barriers that we’re slowly trying to whittle away
at, but they are institutional and outside of our system, so
it’s a group process to work through those together.
Colin: Thank you. What Brianna and I will do is ask a few
questions before punting it to the audience to ask some
questions too. Our first question is, How has increased
awareness of the opioid epidemic changed your practice
of prescribing opioids and counseling patients on their
appropriate use.
Dr. Nash: In the inpatient world, the pendulum has swung
from using opioids to really try other alternatives before
going to opioids for pain management. Most providers
are more aware of the risks and benefits of using opioids.
What’s astounding is that the more I read about chronic
opioid use, the more confused I’ve become. I do worry
about the limits that are being proposed on the number
of morphine equivalents providers can prescribe, leaving

a patient population that are like pain refugees in a way. I
think we really need to evaluate prescribing patterns of
physicians as a whole at our institution, which we’re
beginning to do, and identify variations in practice habits.
This is much like the tenets of quality and safety—where
you evaluate your performance, see where your outliers
are, and address them. Our Opioid Task Force looked at
surgical data, habits of surgeons who were prescribing
narcotics after routine procedures such as cholecystectomy. We called patients a few days after discharge
and found that 60% of these patients’ narcotics were not
being used. That’s a real area of us to evaluate our
prescribing habits, what patients really need, and reduce
the number of opioids in the system that may theoretically
decrease diversion. That’s certainly a way that some
patients become addicted. So I would say that the
pendulum is swinging and prescribers are aware of risks,
but still work needs to be done in evaluating variations in
prescribing patterns.
Dr. Worster: Personally, I have changed my prescribing
practices significantly; I live in the outpatient world. I
probably prescribe opioids nearly every single day. I take
care of patients with cancer, I take care of patients who
are dying. But I think there’s a couple of things that have
really meaningfully contributed to the conversation that
I’m having a lot more with patients. One of them is the
PDMP and I’m so frustrated that Pennsylvania was one of
the last adopters of this nationwide—and for a while we
couldn’t actually query New Jersey or Delaware, so you
had a partial picture but not even the whole picture.
Finally, that’s in place and I think that is something that is
just best practice; everyone that we give a medication to,
we should be looking. The other thing is that public
awareness. I think public understanding of the crisis has
people coming into my office saying, “I’m scared of
opioids.” I just left a patient today who is 70 years old and
has metastatic prostate cancer who basically became
non-ambulatory because he had such bad bony pain but
didn’t want to take opioids because he was scared of
becoming addicted. So as the pendulum swung so far
one way, with pain being the fifth vital sign and us saying
“Everyone needs opioids,” I also do caution that we can’t
throw the baby out with the bathwater here. There is
some goodness to this, and I think the best change that
could be happening out of all of this in terms of prescribing
patterns is that it really becomes an informed conversation
between the patient and the provider. We have to
understand what is driving patients who are either taking
the medication or not, how to take it safely, and how to
get rid of it if they’re not taking it. Eighty percent of the
opioids people take are outside of one physician
prescribing them, so we’re missing the boat in connecting
the dots between “What pill am I going to write for you
today?” and what happens beyond that setting.
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Dr. Nash: I think two things the audience should be aware
of is that there is now a Take-Back box in Jefferon’s
apothecary, open the same hours as that pharmacy,
where you can bring back your medications. You can tell
your patients that the box is available now. I also just got
off the phone with Dr. Jeff Riggio who wanted me to
inform you that the PDMP is going to be integrated into
Epic very soon. You’ll be able to press Care Everywhere
and see the PDMP data if you are registered. This is
another reason Dr. Zavodnick and I are really pressing
house staff to become registered with PDMP because of
its value.
Dr. Kay: One comment I want to make—and, yes, there
are exceptions, but in general—for every patient that I’ve
admitted to the Methadone Clinic who has said, “I had no
addiction until I got the Percocet for this surgery,” that
hasn’t been the case. The problem is, there are things that
are addictions that we don’t consider addictions; when
they were 12 they were smoking a pack a day of cigarettes
or using alcohol heavily or using marijuana on a regular
basis. We sort of throw those out the window. My feeling
is that these are really important things to pick up on and
think about, I think the history is the piece we’re often
missing. I’m not saying that if a patient has that history, it
puts them at risk for future addiction. It’s not that you
wouldn’t give them opioids if necessary, but you might
have a different conversation with them. The thing that
drives me crazy is that I’ll come see one of the methadone
patients at the hospital and when I look at the H&P, it’ll say
“One pack a day of cigarettes, three glasses of wine
occasionally.” By definition, they’re on methadone; they
have a significant addiction history with opioids and
there’s nothing documented. I see a great tobacco and
alcohol history but that really isn’t a surrogate for an
addiction history. I think we have to be much more
thoughtful about the history.
Dr. Zavodnick: I think Dr. Kay made a really good point
about naming the problem, and that’s a big change that
I’ve seen since I was a resident here not terribly long ago.
I thought that when I was a resident our notes would
sometimes inaccurately document the problem, like
“IVDA” or IV Drug Abuse which would be listed in the
social history but nowhere else. We’d have Night Float
getting calls in the middle of the night and who would tell
us, “They’re always asking for this or that,” but no one was
actually naming a diagnosis for them. What I’m seeing
more and more is that when we’re documenting or
talking to the patient or talking to the team, “Opioid Use
Disorder” or “Opioid Addiction” is actually a part of the
problem list and is something we create a plan to address.
Our conversations with patients include what we can do
about symptom management and what we can expect
about pain needs during the admission. What we need to
get better as providers in the Opioid Crisis is to start
treating opioid use disorder as a diagnosis and as a
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problem instead of as some background issue that’s really
only going to be handled by the intern taking pages
overnight.
Colin: We’ve already touched on this a little bit, but what
differences have you noticed in patient attitudes towards
opioids since the opioid epidemic was declared a national
priority?
Dr. Worster: We jokingly say that I’m either begging
someone to take a milligram of morphine or I’m begging
them to stop taking 7,000 milligrams of morphine. That’s
certainly an exaggeration, but I think patient attitudes
have diverged very broadly because of this crisis. Some of
them have this awareness and are scared—and I think we
should all have some healthy fear of opioids—but there
are other patients who say, “I don’t care what you tell me,
this is the only thing that works for me and I’m going to
take it and be damned if you’re going to take it away from
me.” Patients are nervous about it because it’s in the news
and everyone’s talking about it, and all of a sudden, even
the process of getting pain medications is changing. You
can’t go to the ED and walk away with 30 days of a
prescription anymore. I find that it is a more emotionallycharged patient that I see when I’m talking about opioids,
one way or the other. It’s becoming more of a difficult
conversation and I think it’s becoming really important
that we all participate in with these patients. It should be
something that is noted on the problem list and something
we talk about with them directly—not as shaming, not
something that gets marginalized, but something that is a
part of how we best take care of them.
Colin: How does your management differ for patients
with acute care needs as compared to patients admitted
on chronic opioid therapy?
Dr. Zavodnick: I have a very low threshold for calling the
Acute Pain Service. I do remember being taught in medical
school about how likely we are to underdose patients with
opioid dependence and that’s something I worry a lot
about with increased awareness; as we swing the
pendulum potentially too far in the other direction and
find ourselves policing people with chronic pain, deciding
whether their pain is legitimate—“Well, let’s not given them
IV,” “Let’s make sure that they have an outpatient prescriber
so I’m not the one prescribing it.” I can see a lot of fear
from providers as well. I have a low threshold to ask for
help in treating acute on chronic pain because I don’t
know how well I’m going to be able to treat pain with the
medications I have without causing respiratory depression
and so I think about ketamine early. These patients need
more aggressive treatment, not less.
Dr. Nash: It’s almost easier inpatient, because your patient
is monitored. You don’t want something bad to happen
to your patient, but when he or she is on a monitored
unit, it’s easier to make adjustments to treat acute on

chronic pain. My thinking about some of these patients
has changed; I’ve come to realize that patients on
long-acting opioids need that medication almost to feel
normal and function as their normal selves.
Dr. Zavodnick: I’ve also seen the lines between acute and
chronic pain blur; when I see a diagnosis of “Acute on
Chronic Pain,” I’m not sure when we have acute pain and
when we have inadequately managed chronic pain. I
think it’s great that we’ve become more aware of the risks
of narcotics but there are also people who want, expect,
and maybe need these medications who aren’t able to
access them. In the same way I sometimes have difficulty
transitioning heroin users to the outpatient world, I
sometimes have difficulty transitioning chronic pain
patients to the outpatient world because they’re started
on narcotics for chronic pain in the hospital and I’m not
able to find anyone willing to follow them.
Dr. Kay: I just want to make a few quick comments: The
first is to remember that the goal for patients on
methadone maintenance is to get them on a blocking
dose such that if they used any opioids, they would not
get high off of them but would still get pain management.
They can get opioids, the important thing is to make
sure they don’t feel as though it is “stirring up” their
addiction, to ask the question. The other thing is that
when managing patients’ acute or chronic pain, I like to
think of it as a pie and explain to them, “I can’t give you
one pie, but I can give you eight different slices of
different pies to make up a whole pie.” It’s not going to
be that one medicine takes care of everything, pain
management involves a multimodal approach. I also
want them on standing NSAIDs because that will greatly
reduce their opioid needs.
Dr. Worster: I think that’s a great point and emphasizes
the need for education about what pain is. The pathophysiology of pain is very different depending on whether
you’re talking about inflammatory pain or neuropathic
pain or visceral pain. I didn’t get that education and I think
that’s crucial. If you’re trying to treat neuropathic pain with
opioids and the patient’s requiring more and more, no
kidding—neuropathic pain isn’t really responsive to opioids
based on the pathophysiology. There’s a reason why, with
inflammatory pain, you get more bang for your buck
using NSAIDs as opposed to opioids.
Dr. Kay: One more take-away is to ask, “What’s the
patient’s goal with the medication?” One of my NARP
patients was going for a root canal and I suggested he
take 600 milligrams of ibuprofen before the lidocaine
wore off. He told me, “I don’t mind the pain, I want to not
care about the pain.” The opioid would have done that
while the NSAID would not have had that effect.
Sometimes patients take opioids to knock them out, help
them sleep. It’s always worth asking what the patient’s
goal is with the medication.

Brianna: Kate and Meghan, would you be willing to talk
with us about the community resources available to get
our patients plugged in?
Ms. Morley: Sure, I have information up here about our
team and we’re working to get ourselves listed as an
official Consult in Epic. As far as Jefferson goes, we do
have two methadone clinics, the Family Center for
pregnant and parenting woman as well as NARP for
everyone else. My team doesn’t just refer to Jefferson
resources. When patients are admitted to either Jefferson
Main Campus or Methodist, I come in and really lead with
motivational interviewing. Something that I have the
luxury of is time and I know that not everybody has that.
Social work sure doesn’t, you don’t as providers. I
understand that. I can spend 20-30 minutes just having a
conversation with patients about their use and life and
traumas before I even say the word “treatment,” and I
think that having the time to build that relationship is really
important to getting people to that motivational place
where they are open to discussion.
Once patients have decided that they are ready for
treatment, we work in tandem with Social Work to refer
them to appropriate programs—be it methadone,
suboxone, vivitrol (medication-assisted therapies), or even
if they want to go into counseling, we can facilitate those
warm hand-offs and make sure that there’s no gap in
care. The day that they’re being discharged from the
hospital or the following day, they’re being admitted to
whatever program we have decided to send them to. We
can also link them to outpatient providers that aren’t in
the “clinic world” or the “substance abuse world” as a lot
of patients who are professional aren’t going to be able to
engage in those programs because there are often group
or individual therapy sessions that run during the day that
a working individual isn’t going to be able to attend. We’re
able to have conversations with people about what their
life looks like and what program makes the most sense
for them. One of the biggest barriers for us is when a
patient doesn’t have a urine drug screen (UDS). A patient
can’t be admitted to any type of medication-assisted
program without a urine drug screen that’s positive for an
opioid. That’s something we’ve been preaching and
pushing because the lack of a UDS stops people from
being admitted to the program they chose that next day.
Basically without telling them to, we know and they know
they’re going to have to go out and use before being
admitted to these programs. There are other barriers to
these programs like identification and it’s something to
keep in mind when prescribing medication-assisted
therapies as an inpatient—you need to think about the
other documents that are necessary to continue these
therapies as an outpatient. These are the sorts of issues
that my team deals with and we want to be known!
Someone once told me that we’re the best-kept secret
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and Jefferson and we really don’t want to be. We’re trying
to get our name out there as a resource for you.
Dr. Kay: You make a very good point about there being
three types of opioids—natural, semi-synthetic, and
synthetic. Each has a different urine drug screen, you
have to specifically test for methadone and buprenorphine.
If I use heroin today and you just test me for methadone,
I’m going to come up negative and vise-versa.
Ms. Siddiqi: To reinforce what Meghan said, we absolutely
need the UDS. Without it, I can refer until the cows come
home and nothing will happen. The other barrier, as she
mentioned, is the lack of ID. Some clinics are becoming
more receptive to expired ID or are getting copies from
previous treatment centers, but not everywhere. Today I
actually called my colleagues at an agency named BHSI
which helps the uninsured get insurance and, in the
interim, guarantee payment to a clinic so we can get
someone directly in from discharge here who is uninsured.
They have remained very strict about identification, so if
there’s no photo ID, our ability to refer to them at the
moment is limited. I’ve had some arguments with
physicians who prescribe methadone as an inpatient to
keep people in the hospital to receive the rest of their
medical care. On the other hand, starting someone that
we cannot comfortably get into ongoing care after
discharge raises some other ethical issues as well, because
no one will prescribe methadone to someone who is out
in the community but not connected. Another dilemma
that we have as an inpatient related to patients who are on
methadone and need IV antibiotics or wound care for an
extended period of time. We are kind of up the creek as
there are only two facilities in area that accept these
patients as inpatients; one is Kensington Hospital, the
other is Valley Forge. Kensington is in a position now
where they can cherry-pick and only accepts patients on
Medicaid-HMO (not state Medicaid). Valley Forge is difficult
to get into. If you have a patient on state Medicare, we’re
kind of screwed also. Medicare seems to have a bizarre
notion that older people no longer have substance abuse
issues and that’s something that really needs to be
addressed as a society. It’s really criminal, in some respects,
that there is no ongoing access for these patients.
Dr. Kay: Even if you’re not entirely sure the patient will be
followed up as an outpatient, I’d still put someone who
addicted to opioids and is agreeable on methadone
because if you don’t, you run into two problems. First, if
someone just had a heart attack, having them in
withdrawal is really not safe cardiac-wise, with their pulse
racing and blood pressure up. The other issue is that
they’re at high risk of leaving against medical advice. To
get them the proper care and for medical safety, my
feeling is you should be putting them on methadone.
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QUESTIONS
Dr. Emily Stewart: What’s the highest we can safely do
that and then discharge them if they don’t intend to quit?
Dr. Kay: There is no magic number. When I first started
here, I was obsessed with the practice that everyone who
was started on methadone in the hospital had to be
tapered off before discharge. Since then I’ve discovered
that the taper doesn’t really matter and the way that I
think about it now reflects something I’ve picked up from
a colleague of mine—which is to say that they were using
before they came in, unfortunately as much as I’d like to
get everyone into treatment, not everyone is ready and
the reality is that some people are going to leave the
hospital and use again. Another thing to remember is that
often patients’ friends will bring them things into the
hospital. So there is no magic number, but there are, of
course, safety issues with higher and higher doses of
methadone. We could have a whole separate Grand
Rounds about inpatient management of methadone.
Dr. Zavodnick: This is about to get much, much easier.
The treatment subcommittee has been working on a
guideline for inpatient management of patients in
withdrawal. There are a couple different pathways,
including one for patients interested in seeking medicationassistant therapy in the long-term and for whom you’ll
need to consider outpatient care up front. The Center of
Excellence is really great at this, thank you for bringing to
the forefront these new resources for our patients and
making the bridges to outpatient care stronger and
stronger. We’ve included in the guidelines some tips for
the providers overnight, because Psychiatry and Social
Work is all well and good in the morning but we want to
interns on Night Float to have support in caring for
patients’ withdrawal symptoms overnight and at least
begin to have a conversation with the patient about
whether he or she would be open to methadone or
suboxone long-term which could then be started as an
inpatient. We’ll have guidelines about how to start these
medications, how to titrate them, when to call Psychiatry.
Not every patient who comes in is going to be interested
in engaging in treatment and we’re still going to have
guidelines for robust symptom management with
clonidine and Zofran, for example. Just because some
patients might not be interested in methadone doesn’t
mean we don’t want to treat their withdrawal. I think we
as front-line generalist providers are going to get a little
more support in making these decisions for our patients
and saying, “Here are the things we offer for withdrawal
management, which of these do you want to try?” and
“I’m here to partner with you on this inpatient stay and
we’re going to call the Center for Excellence to figure out
an outpatient plan, too.” I think guided inpatient
management of withdrawal and warm hand-offs to
outpatient resources make up the gold standard that we
should all be reaching for with our patients.

Dr. Sarah Rosenberg: As a healthcare system, I can’t help
but feel like we’re completely blowing this in a way that’s
baffling to me. It seems as though politicians and the
laypeople are blaming doctors for the Opioid Crisis but
do you have any tips on how to repair our therapeutic
relationships with patients?
Dr. Worster: What goes hand-in-hand with that are
conversations with patients that are like, “I want it”/”No,
you can’t have it”—this bargaining. I tell people all the
time, “I’m fine with you being angry at me. That’s okay, I
can take that. I need you to hear that all I care about at
the end of the day is providing you with care that is safe.”
Because that’s the first thing we all signed up for here, to
do no harm. I think with empathy, you can communicate
that with a patient. We can say that it’s fine for patients to
feel angry, sad, or frustrated. We hold those emotions for
them. But we need to have realistic one-on-one
conversations with patients about safety, I think that’s
where repairing those therapeutic relationships start. I
think most patients will partner with you if you provide a
safe, non-judgmental space. I think it’s a small minority
that will see you as the cause of the problem or stay angry
with you because you’re not giving them anything at all.

Dr. Kay: I have a ton of experience with this on the benzo
front and have often approached patients with terrible
anxiety by saying, “I don’t think this plan that we’ve had is
working for your anxiety. The Xanax isn’t cutting it, we
need to do better. Let’s come up with another plan.”
Dr. Suchit Bhutani: I know the emergency room (ER) is a
place of first-exposure for many patients. There are some
centers in New Jersey which have advertised “Opioid-Free
ERs,” is that something that we’ve considered or could be
changing here?
Dr. Worster: If you look at this on a larger level, the
number of total ER opioid prescriptions over the last few
years have gone down. Now, it defaults to a 72-hour
prescription instead of seven or 10 days. I don’t see how
you can provide great, individualized care to people by
making blanket statements. That’s like saying, “Listen, I just
don’t do antibiotics, so we will never give you antibiotics.”
We also can’t just stop providing good medical care. Our
ER providers are very engaged in this problem. If they see
my name in the PDMP, they’ll give me a call and I’m happy
to have that conversation with someone. That’s what we
really need to do, to increase our communication about
this problem.

Dr. Rebecca Jaffe: I’d like to commend that approach
because I think what I’ve seen over the last five years is a
discomfort about what’s happening and an unwillingness
to engage in that partnership. You’ll see people saying,
“Well, I can’t prescribe that for you,” or “My clinic won’t
prescribe opioids,” and that’s very different from a
harm-reduction strategy where you might say, “This is the
current state of where we are, this is where we plan to go
long-term, what are the steps to get there?” Talk about the
different things that we can do with patients to improve
safety and build partnership.
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